Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort.
Casale M, Forni GL, Cassinerio E, Pasquali D, Origa R, Serra M, Campisi S, Peluso A, Renni R, Cattoni A, De Michele E, Allò M, Poggi M, Ferrara F, Di Concilio R, Sportelli F, Quarta A, Putti MC, Notarangelo LD, Sau A, Ladogana S, Tartaglione I, Picariello S, Marcon A, Sturiale P, Roberti D, Lazzarino AI, Perrotta S. Casale M, et al. Among authors: forni gl. Haematologica. 2022 Feb 1;107(2):467-477. doi: 10.3324/haematol.2020.272419. Haematologica. 2022. PMID: 33406815 Free PMC article.
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Piga A, et al. Among authors: forni gl. Haematologica. 2006 Jul;91(7):873-80. Haematologica. 2006. PMID: 16818273 Clinical Trial.
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, Balez S, Alberti D, Séchaud R. Galanello R, et al. Among authors: forni gl. J Clin Pharmacol. 2008 Apr;48(4):428-35. doi: 10.1177/0091270007313327. Epub 2008 Feb 15. J Clin Pharmacol. 2008. PMID: 18281442 Clinical Trial.
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF. Vichinsky E, et al. Among authors: forni gl. Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11. Acta Haematol. 2008. PMID: 18408362 Clinical Trial.
Cholelithiasis in thalassemia major.
Origa R, Galanello R, Perseu L, Tavazzi D, Domenica Cappellini M, Terenzani L, Forni GL, Quarta G, Boetti T, Piga A. Origa R, et al. Among authors: forni gl. Eur J Haematol. 2009 Jan;82(1):22-5. doi: 10.1111/j.1600-0609.2008.01162.x. Epub 2008 Oct 31. Eur J Haematol. 2009. PMID: 19021734
Pregnancy and beta-thalassemia: an Italian multicenter experience.
Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R. Origa R, et al. Among authors: forni gl. Haematologica. 2010 Mar;95(3):376-81. doi: 10.3324/haematol.2009.012393. Epub 2009 Nov 10. Haematologica. 2010. PMID: 19903676 Free PMC article.
172 results